2026 — CAR-T in autoimmune rheumatic disease (Mackensen-platform landscape)
One-paragraph summary
Review of cellular therapies — particularly CAR-T (chimeric antigen receptor-modified lymphocytes) — for autoimmune rheumatic disease. Autologous and emerging allogeneic CAR-T platforms now offer the possibility of "deep, drug-free remission" in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), and related conditions for which conventional therapies remain inadequate. Reviews rationale, current clinical experience, safety profile, and future directions, with focus on efficacy and immune-system reconstitution after CD19+ B-cell-lineage depletion. For the project, this characterizes the landscape that the FM advanced-therapy tier's Mackensen-protocol activation trigger depends on. Watchlist activation trigger (a) requires Mackensen CAR-T durability across two distinct severe autoimmune indications at 24-month follow-up — this review documents that CAR-T is now in serious clinical consideration across SLE / IIM / SSc, but does not yet report the cross-indication durability data the activation trigger needs.
Claims as triples
car_t_therapy — bridges → fm_autoimmune[evidence: cross-condition autoimmune CAR-T landscape; if Mackensen-protocol succeeds, FM-extension feasibility increases; confidence: bridging]car_t_therapy — modulates → autoantibody_mediated_pain[evidence: CD19+ B-cell-lineage depletion → reduced antibody production; mechanism review; confidence: emerging]
Triangulation notes
- Anchor citation for the advanced-therapy tier WATCH-LIST entry in cure-path-arm-decisions.md.
- Documents the landscape that needs to consolidate before the FM advanced-therapy tier activation trigger fires.
- Discovered via watchlist query WL-2 (Mackensen CAR-T). Does not constitute activation trigger by itself; ingested as landscape characterization.